Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke

Abstract

Based on analysis of total intent-to-treat and per-protocol populations only, this is a negative trial that also raises safety concerns, particularly in patients receiving systemic thrombolysis.